CHS-828 is a pyridyl cyanoguanidine anti-tumor agent that has been identified as a competitive inhibitor of Nampt as well as an inhibitor of NF-κB pathway activity. CHS-828 has potent cytotoxic effects in human breast (IC50 = 7.3 nM) and lung cancer (IC50 = 0.5 nM) cells both in vitro and in vivo. In nude mice bearing human tumor xenografts, CHS-828, at 20-50 mg/kg/day, inhibits the growth of MCF-7 breast cancer tumors and induces regression of NYH small cell lung cancer tumors.
GMX1778 is an anticancer agent that inhibits cellular synthesis of NAD.
ChEBI: 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine is an aromatic ether.
1) Olesen?et al.?(2008),?Anticancer agent CHS-828 inhibits cellular synthesis of NAD; Biochem. Biophys. Res. Commun.?376?799
2) Hassan?et al. (2006),?CHS 828 kill tumor cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome; Anticancer Res.?26?4431
3) Hjarnaa?et al.?(1999),?CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo; Cancer Res.?59?5751
4) Cerna?et al.?(2012)?Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner; J. Biol. Chem.?287?22408
